See more : Actelis Networks, Inc. (ASNS) Income Statement Analysis – Financial Results
Complete financial analysis of Braxia Scientific Corp. (BRAX.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Braxia Scientific Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Morris Home Holdings Limited (1575.HK) Income Statement Analysis – Financial Results
- TetraLogic Pharmaceuticals Corporation (TLOG) Income Statement Analysis – Financial Results
- PT Ciputra Development Tbk (CTRA.JK) Income Statement Analysis – Financial Results
- Zhihu Inc. (2390.HK) Income Statement Analysis – Financial Results
- Umatrin Holding Limited (UMHL) Income Statement Analysis – Financial Results
Braxia Scientific Corp. (BRAX.CN)
About Braxia Scientific Corp.
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. Braxia Scientific Corp. is headquartered in Toronto, Ontario.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 1.88M | 1.49M | 1.01M | 212.00 |
| Cost of Revenue | 1.71M | 1.24M | 862.71K | 9.16K |
| Gross Profit | 171.74K | 246.87K | 145.67K | -8.95K |
| Gross Profit Ratio | 9.12% | 16.60% | 14.45% | -4,219.81% |
| Research & Development | 98.35K | 192.58K | 1.98M | 50.00K |
| General & Administrative | 5.47M | 6.91M | 6.84M | 68.28K |
| Selling & Marketing | 152.44K | 253.00K | 1.85M | 7.65K |
| SG&A | 5.62M | 7.17M | 8.69M | 113.52K |
| Other Expenses | 1.93M | -186.55K | -129.02K | 0.00 |
| Operating Expenses | 7.65M | 7.17M | 10.67M | 163.52K |
| Cost & Expenses | 9.36M | 8.41M | 11.53M | 172.68K |
| Interest Income | 0.00 | 4.95K | 3.27K | 0.00 |
| Interest Expense | 17.84K | 4.95K | 3.26K | 0.00 |
| Depreciation & Amortization | 565.88K | 23.17K | 19.80K | 2.07K |
| EBITDA | -12.72M | -12.15M | -88.43M | -170.66K |
| EBITDA Ratio | -675.17% | -464.37% | -1,041.88% | -80,377.36% |
| Operating Income | -7.48M | -7.13M | -10.53M | -172.47K |
| Operating Income Ratio | -397.00% | -479.42% | -1,043.84% | -81,353.77% |
| Total Other Income/Expenses | -5.81M | -5.05M | -78.29M | -253.00 |
| Income Before Tax | -13.29M | -12.18M | -88.83M | -172.72K |
| Income Before Tax Ratio | -705.22% | -818.97% | -8,809.07% | -81,473.11% |
| Income Tax Expense | -145.88K | -45.27K | 3.26K | -1.00 |
| Net Income | -13.14M | -12.13M | -88.83M | -172.72K |
| Net Income Ratio | -697.48% | -815.93% | -8,809.07% | -81,473.11% |
| EPS | -0.06 | -0.07 | -0.56 | 0.00 |
| EPS Diluted | -0.06 | -0.07 | -0.56 | 0.00 |
| Weighted Avg Shares Out | 228.42M | 175.24M | 157.64M | 39.44M |
| Weighted Avg Shares Out (Dil) | 228.42M | 175.24M | 157.64M | 39.44M |
Source: https://incomestatements.info
Category: Stock Reports